: Pfizer Contacts

UPLYSO (alfataliglicerase) Approved

in Brazil by ANVISA for the Treatment of Gaucher Disease

New York, NY and Carmiel, Israel - March 18, 2013

- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the Brazilian National

Health Surveillance Agency (ANVISA, Agencia Nacional de Vigilancia Sanitaria) has granted regulatory approval to UPLYSO

(alfataliglicerase) for the long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease.

Gaucher disease is a rare lysosomal storage disorder that affects approximately 10,000 people worldwide.

UPLYSO is known as ELELYSO (taliglucerase alfa) outside

of Latin America. ELELYSO was approved by the United States Food and Drug Administration in May 2012 and by Israel's Ministry of

Health in September 2012 for the long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type I Gaucher

disease. The ANVISA approval comes after the approval of UPLYSO by the Ministry of Public Health in Uruguay in November 2012.

"ANVISA's approval of UPLYSO demonstrates Pfizer's

ability to successfully bring therapies for rare diseases to the marketplace," said Diem Nguyen, Ph.D., MBA, general manager,

Pfizer Biosimilars. "We are committed to the Gaucher community and look forward to continuing to work closely with our partner

Protalix toward our goal of bringing UPLYSO to those living with Gaucher throughout Latin America."

UPLYSO is the first plant cell-based ERT for the treatment of

Gaucher disease. It is also the first approved plant cell-expressed drug that is derived from ProCellEx , Protalix's

proprietary plant cell-based protein manufacturing system, using genetically engineered carrot cells. UPLYSO is a form of the human

lysosomal enzyme, glucocerebrosidase, used to treat Gaucher disease.

"The approval of UPLYSO provides an important treatment

option for those in Brazil using enzyme replacement therapy to manage their Gaucher disease and demonstrates the potential of our

plant cell manufacturing technology," said David Aviezer, Ph.D., MBA, president and chief executive officer of Protalix BioTherapeutics.

On November 30, 2009, Protalix entered into an agreement with

Pfizer to develop and commercialize taliglucerase alfa/alfataliglicerase. Under the terms of the agreement, Protalix retained the

exclusive commercialization rights in Israel, while Pfizer received exclusive licensing rights for commercialization in all other

Indication for UPLYSO in Brazil

UPLYSO (alfataliglicerase) is indicated for long-term enzyme

replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. The manifestations of Gaucher disease may

include one or more of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone disease.

Important Safety Information for UPLYSO in Brazil

As with any intravenous protein medicine,

like enzyme replacement therapy (ERT), UPLYSO may cause infusion-related reactions (i.e., occurring during or shortly after infusion)

and hypersensitivity reactions. If a severe allergic reaction occurs, immediate discontinuation of the alfataliglicerase infusion

is recommended. Patients who experience reactions of hypersensitivity or related to the infusion, can however be managed successfully.

The therapy can be continued by slowing the infusion rate, treating with medicinal products such as antihistamines, antipyretics

and/or corticosteroids, and/or stopping and resuming treatment with decreased infusion rate. Pre-treatment with antihistamines

and/or corticosteroids may prevent subsequent reactions.

The most commonly observed infusion reactions were headache,

hypersensitivity (allergic reaction), dizziness, flushing (redness), throat irritation, nausea (qualm), pruritus (itch), erythema

(redness), rash, bone pain, back pain, arthralgia (joint pain), among others.

Also, there is a possibility of developing

antibodies to UPLYSO. However, it is currently unclear whether this has an impact on the clinical response or adverse reactions.

Patients with an immune response to other ERTs who are switching to UPLYSO should continue to be monitored for antibodies. Patients

who have developed infusion or immune reactions with UPLYSO or with another ERT should be monitored for antidrug antibodies when

being treated with UPLYSO.

If you are pregnant, or plan to become

pregnant, you should talk to your doctor about potential benefits and risks.

Indication for ELELYSO in the U.S.

ELELYSO (taliglucerase alfa)

for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT)

for adults with a confirmed diagnosis of Type 1 Gaucher disease.

Important Safety Information for

As with any intravenous protein medicine,

like enzyme replacement therapy (ERT), severe allergic reactions (including anaphylaxis) have been observed in patients treated

with ELELYSO. If this occurs, ELELYSO should be immediately discontinued, and appropriate medical treatment should be initiated.

Patients who have experienced anaphylaxis to ELELYSO or another ERT should proceed with caution upon retreatment.

In addition, infusion reactions (including

allergic reactions)-defined as a reaction occurring within 24 hours of the infusion-were the most commonly observed

reactions to ELELYSO. The most commonly observed infusion reactions were headache, chest pain or discomfort, weakness, fatigue,

hives, abnormal redness of the skin, increased blood pressure, back or joint pain, and flushing. Other infusion or allergic reactions

included swelling of the face, mouth, and/or throat; wheezing; shortness of breath; skin color turning blue; coughing; and low

blood pressure. Most of these reactions were mild and did not require treatment.

Management of infusion reactions is

based on the type and severity of the reaction. Your doctor may manage infusion reactions by temporarily stopping the infusion,

slowing the infusion rate, or treating with medications such as an antihistamine and/or a fever reducer. Treatment with antihistamines

and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions.

Other common adverse reactions observed

were upper respiratory tract infections, throat infection, flu, urinary tract infection, and pain in extremities.

As with all therapeutic proteins, including

ERTs, there is a possibility of developing antibodies to ELELYSO. However, it is currently unclear whether this has an impact on

the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to ELELYSO should

continue to be monitored for antibodies. Comparison of the frequency of antibodies across ERTs may be misleading. Patients who

have developed infusion or immune reactions with ELELYSO or with another ERT should be monitored for antidrug antibodies when being

treated with ELELYSO.

If you are pregnant, or plan to become

pregnant, you should talk to your doctor about potential benefits and risks.

The health information contained herein

is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions

regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

This product information is intended

only for residents of the United States.

You are encouraged to report negative

side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Gaucher Disease

Gaucher disease is an inherited lysosomal storage disorder in

humans that affects an estimated 10,000 people worldwide and can cause severe and debilitating symptoms, including: enlargement

of the liver and spleen, various forms of bone disease, easy bruising and anemia (a low number of red blood cells). Gaucher disease

consists of varying degrees of severity; it has been sub-divided into three subtypes-Types 1, 2 and 3-according to

the presence or absence of neurological involvement. Type 1, the most common, is found at a higher frequency among individuals

who are of Ashkenazi Jewish ancestry.

Pfizer Inc.: Working together for a healthier world

At Pfizer, we apply science and our global resources to bring

therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety

and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines

and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across

developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of

our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate

with health care providers, governments and local communities to support and expand access to reliable, affordable health care

around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn